Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection
Brief Summary: To establish that at least 1 dose of daclatasvir combined with standard of care (pegylated interferon and ribavirin) is safe and well tolerated and demonstrates extended rapid virologic response rates at least 35% greater than those with placebo.


Options:
A: Arm Label: Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: peg-interferon alfa-2a, Drug: ribavirin | Arm Label: Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: peg-interferon alfa-2a, Drug: ribavirin | Arm Label: Placebo plus peg-interferon alfa-2a and ribavirin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: peg-interferon alfa-2a, Drug: ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus peg-interferon alfa-2a and ribavirin | Intervention Type: DRUG; Name: peg-interferon alfa-2a; Assigned to Arm(s): Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg), Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg), Placebo plus peg-interferon alfa-2a and ribavirin | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Daclatasvir plus peg-interferon alfa-2a and ribavirin (20 mg), Daclatasvir plus peg-interferon alfa-2a and ribavirin (60 mg), Placebo plus peg-interferon alfa-2a and ribavirin
B: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 5; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Arm Label: Group 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Daclatasvir, Drug: Placebo | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4, Group 5, Group 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4, Group 5, Group 6
C: Arm Label: Sofosbuvir 200 mg (Genotype 1); Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: Placebo to match sofosbuvir, Drug: PEG, Drug: RBV | Arm Label: Sofosbuvir 400 mg (Genotype 1); Type: EXPERIMENTAL; Interventions: Drug: PEG, Drug: RBV | Arm Label: Placebo (Genotype 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo to match sofosbuvir, Drug: PEG, Drug: RBV | Arm Label: Sofosbuvir 400 mg (Genotype 2/3); Type: EXPERIMENTAL; Interventions: Drug: Sofosbuvir, Drug: PEG, Drug: RBV | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Sofosbuvir 200 mg (Genotype 1), Sofosbuvir 400 mg (Genotype 2/3) | Intervention Type: DRUG; Name: Placebo to match sofosbuvir; Assigned to Arm(s): Placebo (Genotype 1), Sofosbuvir 200 mg (Genotype 1) | Intervention Type: DRUG; Name: PEG; Assigned to Arm(s): Placebo (Genotype 1), Sofosbuvir 200 mg (Genotype 1), Sofosbuvir 400 mg (Genotype 1), Sofosbuvir 400 mg (Genotype 2/3) | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): Placebo (Genotype 1), Sofosbuvir 200 mg (Genotype 1), Sofosbuvir 400 mg (Genotype 1), Sofosbuvir 400 mg (Genotype 2/3)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Intervention Type: DRUG; Name: BMS-791325; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1, 2, 3, 4

Answer: A